Tags

Type your tag names separated by a space and hit enter

Pretreatment with isradipine, a calcium-channel blocker, does not attenuate the acute behavioral effects of ethanol in humans.
Alcohol Clin Exp Res. 1998 Apr; 22(2):539-47.AC

Abstract

The acute subject-rated, performance-impairing, and physiological effects of ethanol (0, 0.5, and 1 g/kg) were examined after pretreatment with isradipine (0, 5, and 10 mg) in nine healthy volunteers. Volunteers received 1 of the 9 ethanol-isradipine combinations during each of nine experimental sessions. Ethanol alone produced prototypical subject-rated drug effects (e.g., increased ratings of "Drunk," "Good effects," and "Like drug") and impaired performance. Isradipine alone also produced significant subject-rated drug effects (e.g., increased ratings of "Drug effect," "Bad effects," "High," and "Stimulated"), but did not impair performance. Isradipine pretreatment generally did not significantly alter the subject-rated or performance-impairing effects of ethanol. Isradipine alone, but not ethanol alone, significantly decreased systolic and diastolic blood pressure. The ethanol-isradipine combinations generally produced significantly greater decreases in blood pressure than were observed with isradipine alone. Breath-alcohol levels were significantly lower after isradipine pretreatment, which suggests isradipine altered the bioavailability of ethanol. The present findings extend previous studies with humans that examined the behavioral effects of ethanol after pretreatment with other calcium-channel blockers, including nifedipine, nimodipine, and verapamil. Whereas the available studies suggest that calcium-channel blockers would not be useful pharmacological adjuncts in the management of ethanol abuse, more research is needed. Future studies should use self-administration and drug discrimination procedures adapted for use with humans to determine if calcium-channel blockers can attenuate any of the behavioral effects of ethanol.

Authors+Show Affiliations

Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson 39216, USA.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9581666

Citation

Rush, C R., and P J. Pazzaglia. "Pretreatment With Isradipine, a Calcium-channel Blocker, Does Not Attenuate the Acute Behavioral Effects of Ethanol in Humans." Alcoholism, Clinical and Experimental Research, vol. 22, no. 2, 1998, pp. 539-47.
Rush CR, Pazzaglia PJ. Pretreatment with isradipine, a calcium-channel blocker, does not attenuate the acute behavioral effects of ethanol in humans. Alcohol Clin Exp Res. 1998;22(2):539-47.
Rush, C. R., & Pazzaglia, P. J. (1998). Pretreatment with isradipine, a calcium-channel blocker, does not attenuate the acute behavioral effects of ethanol in humans. Alcoholism, Clinical and Experimental Research, 22(2), 539-47.
Rush CR, Pazzaglia PJ. Pretreatment With Isradipine, a Calcium-channel Blocker, Does Not Attenuate the Acute Behavioral Effects of Ethanol in Humans. Alcohol Clin Exp Res. 1998;22(2):539-47. PubMed PMID: 9581666.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pretreatment with isradipine, a calcium-channel blocker, does not attenuate the acute behavioral effects of ethanol in humans. AU - Rush,C R, AU - Pazzaglia,P J, PY - 1998/5/15/pubmed PY - 1998/5/15/medline PY - 1998/5/15/entrez SP - 539 EP - 47 JF - Alcoholism, clinical and experimental research JO - Alcohol. Clin. Exp. Res. VL - 22 IS - 2 N2 - The acute subject-rated, performance-impairing, and physiological effects of ethanol (0, 0.5, and 1 g/kg) were examined after pretreatment with isradipine (0, 5, and 10 mg) in nine healthy volunteers. Volunteers received 1 of the 9 ethanol-isradipine combinations during each of nine experimental sessions. Ethanol alone produced prototypical subject-rated drug effects (e.g., increased ratings of "Drunk," "Good effects," and "Like drug") and impaired performance. Isradipine alone also produced significant subject-rated drug effects (e.g., increased ratings of "Drug effect," "Bad effects," "High," and "Stimulated"), but did not impair performance. Isradipine pretreatment generally did not significantly alter the subject-rated or performance-impairing effects of ethanol. Isradipine alone, but not ethanol alone, significantly decreased systolic and diastolic blood pressure. The ethanol-isradipine combinations generally produced significantly greater decreases in blood pressure than were observed with isradipine alone. Breath-alcohol levels were significantly lower after isradipine pretreatment, which suggests isradipine altered the bioavailability of ethanol. The present findings extend previous studies with humans that examined the behavioral effects of ethanol after pretreatment with other calcium-channel blockers, including nifedipine, nimodipine, and verapamil. Whereas the available studies suggest that calcium-channel blockers would not be useful pharmacological adjuncts in the management of ethanol abuse, more research is needed. Future studies should use self-administration and drug discrimination procedures adapted for use with humans to determine if calcium-channel blockers can attenuate any of the behavioral effects of ethanol. SN - 0145-6008 UR - https://www.unboundmedicine.com/medline/citation/9581666/Pretreatment_with_isradipine_a_calcium_channel_blocker_does_not_attenuate_the_acute_behavioral_effects_of_ethanol_in_humans_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0145-6008&date=1998&volume=22&issue=2&spage=539 DB - PRIME DP - Unbound Medicine ER -